FI20115870A0 - Neuroprotective cell penetrating peptides - Google Patents

Neuroprotective cell penetrating peptides

Info

Publication number
FI20115870A0
FI20115870A0 FI20115870A FI20115870A FI20115870A0 FI 20115870 A0 FI20115870 A0 FI 20115870A0 FI 20115870 A FI20115870 A FI 20115870A FI 20115870 A FI20115870 A FI 20115870A FI 20115870 A0 FI20115870 A0 FI 20115870A0
Authority
FI
Finland
Prior art keywords
peptides
seq
disease
amino acids
penetrating peptides
Prior art date
Application number
FI20115870A
Other languages
Finnish (fi)
Swedish (sv)
Inventor
Urmas Arumaee
Mart Saarma
Pia Runeberg-Roos
Original Assignee
Urmas Arumaee
Mart Saarma
Pia Runeberg-Roos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urmas Arumaee, Mart Saarma, Pia Runeberg-Roos filed Critical Urmas Arumaee
Priority to FI20115870A priority Critical patent/FI20115870A0/en
Publication of FI20115870A0 publication Critical patent/FI20115870A0/en
Priority to PCT/FI2012/050859 priority patent/WO2013034805A1/en
Priority to EP12830062.1A priority patent/EP2753641A4/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to the fields of bioactive peptides and cell-penetrating peptides as well as to the field of neurotrophic factors, i.e. growth factors for neural cells. The present invention provides peptides with length of 4 to 40 amino acids comprising the sequence CKGC (SEQ ID NO:1 ) or CRAC (SEQ ID NO:2). Pharmaceutical compositions comprising said peptides are also provided as well as the peptides for use in the treatment of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke, peripheral neuropathy, epilepsy, diabetes or drug addiction. The invention is also directed to a method for promoting survival of dopaminergic neurons. In addition, peptides with length of 4 to 40 amino acids comprising the sequence CXXC (SEQ ID NO: 5) for use in the above mentioned diseases are also provided.
FI20115870A 2011-09-05 2011-09-05 Neuroprotective cell penetrating peptides FI20115870A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FI20115870A FI20115870A0 (en) 2011-09-05 2011-09-05 Neuroprotective cell penetrating peptides
PCT/FI2012/050859 WO2013034805A1 (en) 2011-09-05 2012-09-05 Neuroprotective cell-penetrating peptides
EP12830062.1A EP2753641A4 (en) 2011-09-05 2012-09-05 Neuroprotective cell-penetrating peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20115870A FI20115870A0 (en) 2011-09-05 2011-09-05 Neuroprotective cell penetrating peptides

Publications (1)

Publication Number Publication Date
FI20115870A0 true FI20115870A0 (en) 2011-09-05

Family

ID=44718780

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20115870A FI20115870A0 (en) 2011-09-05 2011-09-05 Neuroprotective cell penetrating peptides

Country Status (3)

Country Link
EP (1) EP2753641A4 (en)
FI (1) FI20115870A0 (en)
WO (1) WO2013034805A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508155A (en) 2012-01-24 2015-03-16 ユニバーシティ オブ マサチューセッツ Soluble MANF in pancreatic beta cell injury
WO2014191630A2 (en) * 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
EP3113788A4 (en) 2014-03-05 2017-10-18 Lawrence M. Schwartz Methods and compositions for the protection of sensory cells
WO2015149005A1 (en) * 2014-03-28 2015-10-01 Buck Institute For Research On Aging Methods and compositions for modulating the immune system
US20170157243A1 (en) * 2014-06-24 2017-06-08 University Of Massachusetts MANF as a Regulator of Immune System Function
EP3377089B1 (en) 2015-11-18 2020-04-08 Herantis Pharma Plc Compositions comprising cdnf for use in the intranasal treatment of central nervous system diseases
MX2019013157A (en) 2017-05-04 2020-08-03 Helsingin Yliopisto C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof.
SG11202009341TA (en) 2018-03-29 2020-10-29 Helsingin Yliopisto C-terminal cdnf fragments, pharmaceutical compositions comprising same and uses thereof
EP3838912A1 (en) 2019-12-20 2021-06-23 Herantis Pharma Oyj Retro-inverso peptides
EP3838345A1 (en) 2019-12-20 2021-06-23 Herantis Pharma Oyj Macrocyclic peptides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043693A1 (en) * 1998-02-26 1999-09-02 Human Genome Sciences, Inc. 36 human secreted proteins
EP1265582A2 (en) * 1999-09-29 2002-12-18 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US20030109457A1 (en) * 2001-10-25 2003-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress
WO2002074956A2 (en) * 2001-03-20 2002-09-26 Prescient Neuropharma Inc. Dopaminergic neuronal survival-promoting factors and uses thereof
CA2441327A1 (en) * 2001-03-30 2002-10-10 Geneprot, Inc. Human arginine-rich protein-related compositions
EP2412719A1 (en) * 2002-12-02 2012-02-01 Xenome Ltd Chi-conotoxin peptides
ATE480559T1 (en) * 2005-12-14 2010-09-15 Licentia Ltd USES OF A NEUROTROPHIC FACTOR
FI20080326A0 (en) * 2008-04-30 2008-04-30 Licentia Oy Neurotrophic factor MANF and its uses

Also Published As

Publication number Publication date
EP2753641A1 (en) 2014-07-16
WO2013034805A1 (en) 2013-03-14
EP2753641A4 (en) 2015-06-24

Similar Documents

Publication Publication Date Title
FI20115870A0 (en) Neuroprotective cell penetrating peptides
MX359516B (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition.
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
NZ703341A (en) Compositions comprising apomorphine and organic acids and uses thereof
NZ621868A (en) Growth hormone polypeptides and methods of making and using same
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
MX2013013833A (en) Compositions, uses and methods for treatment of metabolic disorders and diseases.
TN2014000109A1 (en) Fusion proteins for treating metabolic disorders
NZ611878A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
MX2012001194A (en) Antigenic tau peptides and uses thereof.
CY1112241T1 (en) Peptide Fragments for Stimulating Protein Extracellular Matrix Synthesis
MX2012002502A (en) Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids.
EA201491155A1 (en) NEW MUTANT PRO-NRF AND THEIR APPLICATION TO GET BETA-NRF
UY33222A (en) Amino acid sequences directed against TRAIL cell surface receptor 2, compounds, constructs and effective variants
UA113962C2 (en) PHARMACEUTICAL COMPOSITION CONTAINING APOMORPHINE AS AN ACTIVE INGREDIENT
MX2013010910A (en) Neuroprotective peptides.
UA107836C2 (en) Treatment of alzheimer's disease
EA201290856A1 (en) STABILIZED PHARMACEUTICAL COMPOSITION
NZ590469A (en) Treatment of rheumatoid arthritis with human beta defensins (1-4)
RU2492163C2 (en) Cinnamic acid compounds (versions), intermediate compounds for their obtaining, based on them pharmaceutical composition, method of inhibiting histone diacetase, method of treating diabetes, method of treating tumour or disease associated with cell proliferation, method of enhancing axon growth and method of treating neurodegenerative diseases and spinal muscular atrophy
EA201591108A1 (en) HUMAN GROWTH HORMON AND ALBUMIN, COMPOSITIONS AND THEIR APPLICATIONS
MX2017002476A (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition.
PH12015502005B1 (en) New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy
RU2013111675A (en) RECOMBINANT FC-HYBRID PROTEIN OF THE FIFTH DOMAIN FIBRONECTIN TYPE III DCC
NZ629964A (en) Method for treating inflammation

Legal Events

Date Code Title Description
FD Application lapsed